Skip to main content
SpringerLink
Log in
Birkhäuser
Book cover

Advances in Targeted Cancer Therapy

  • Book
  • © 2005

Overview

Editors:
  1. Paul L. Herrling

    1. Novartis International AG, Basel, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Alex Matter

    1. Novartis Institute for Tropical Diseases, Singapore, Singapore

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Richard M. Schultz

    1. Indianapolis, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Excellent overview of new approaches for the treatment of cancer
  • Covers a large range of molecular targets
  • Discusses the potential for clinical application

Part of the book series: Progress in Drug Research (PDR, volume 63)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages i-vii
    Download chapter PDF

  2. Dawn of a new era in molecular cancer therapeutics

    • Richard M. Schultz
    Pages 1-17

  3. Obtacles and opportunities in the clinical development of targeted therapeutics

    • Grace K. Dy, Alex A. Adjei
    Pages 19-41

  4. Tumor models for preclinical development of targeted agents

    • Beverly A. Teicher
    Pages 43-66

  5. Angiogenesis inhibitors: What is the clinical future?

    • Henk M. W. Verheul, Herbert M. Pinedo
    Pages 67-91

  6. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy

    • Fortunato Ciardiello, Ferdinando De Vita
    Pages 93-115

  7. Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development

    • Grace Choy, Jun-Wei Liu, Dhyan Chandra, Dean G. Tang
    Pages 115-145

  8. Targeted histone deacetylase inhibition for cancer prevention and therapy

    • Carlo Palmieri, R. Charles Coombes, David M. Vigushin
    Pages 147-191

  9. Inhibitors of cyclin-dependent kinase modulators for cancer therapy

    • Adrian M. Senderowicz
    Pages 183-206

  10. Targeting cyclooxygenase-2 for cancer prevention and treatment

    • Stephen T. Gately
    Pages 207-225

  11. Antisense approaches in drug discovery and development

    • Elizabeth Rayburn, Wei Wang, Ruiwen Zhang, Hui Wang
    Pages 227-274

  12. Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate

    • Richard M. Schultz
    Pages 275-300

  13. Back Matter

    Pages 301-303
    Download chapter PDF
Back to top

Keywords

About this book

There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy.

This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed.
This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.

Editors and Affiliations

  • Novartis International AG, Basel, Switzerland

    Paul L. Herrling

  • Novartis Institute for Tropical Diseases, Singapore, Singapore

    Alex Matter

  • Indianapolis, USA

    Richard M. Schultz

Bibliographic Information

  • Book Title: Advances in Targeted Cancer Therapy

  • Editors: Paul L. Herrling, Alex Matter, Richard M. Schultz

  • Series Title: Progress in Drug Research

  • DOI: https://doi.org/10.1007/3-7643-7414-4

  • Publisher: Birkhäuser Basel

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Birkhäuser Basel 2005

  • Hardcover ISBN: 978-3-7643-7174-6Published: 16 September 2005

  • eBook ISBN: 978-3-7643-7414-3Published: 24 January 2006

  • Series ISSN: 0071-786X

  • Series E-ISSN: 2297-4555

  • Edition Number: 1

  • Number of Pages: VII, 303

  • Topics: Cancer Research, Molecular Medicine

Publish with us

Policies and ethics

Back to top

Search

Navigation